Phase II study of FOLFIRI+Ramucirumab with early recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine(RAINCLOUD)
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2643874
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: FOLFIRI+Ramucirumab (5-FU(bolus): 400mg/m2 on day1, 5-FU(ci): 2,400mg/m2 on day1-3 (46hr), l-LV: 200mg/m2 on day1, CPT-11: 180*mg/m2 on day1, Ramucirumab: 8mg/kg on day1) *Allow dose level -1 (150mg/m2)
Primary outcome(s): Progression-Free Survival (PFS)
Study Design: Single arm Non-randomized
创建时间：
2017-08-15
